Atea Pharmaceuticals, Inc.
Clinical trials sponsored by Atea Pharmaceuticals, Inc., explained in plain language.
Biopharmaceutical company developing antiviral therapies.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New pill combo aims to cure hepatitis c in just 8 weeks
Disease control CompletedThis study tested a new combination of two antiviral pills, bemnifosbuvir and ruzasvir, taken once daily for 8 weeks in 275 adults with chronic hepatitis C. The main goal was to see if the virus was still undetectable 12 weeks after treatment ended. The trial is now complete, and…
Phase: PHASE2 • Sponsor: Atea Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Early safety check: new drug combo tested in kidney and liver patients
Knowledge-focused CompletedThis early-stage study is testing a single dose of the drug combination bemnifosbuvir/ruzasvir in 28 adults. Some participants have severe kidney or liver impairment, while others are healthy. The goal is to see how the body processes the drug and whether it is safe in these grou…
Phase: PHASE1 • Sponsor: Atea Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Birth control pill interaction study completed for experimental hepatitis c drug
Knowledge-focused CompletedThis study looked at whether taking an experimental hepatitis C medication (bemnifosbuvir/ruzasvir) changes how birth control pills work in the body. 24 healthy women who cannot become pregnant took the hepatitis C drug along with a single dose of a common birth control pill. The…
Phase: PHASE1 • Sponsor: Atea Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC